Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

大约70%的晚期乳腺癌为激素受体阳性HER2阴性，主要依靠内分泌治疗和化疗。对于内分泌治疗耐药患者，虽然细胞周期蛋白依赖性激酶CDK4/6抑制剂有效，但是仍然可能发生耐药。乳腺癌命运第四交响曲（DESTINY-Breast04）研究已经证实，德曲妥珠 ...

The combination of trastuzumab biosimilar and pertuzumab with chemotherapy was effective in treating HER2-positive breast cancer, offering high safety and affordability. HER2-positive breast cancer ...

In a 10-year analysis of the ShortHER trial, high tumor-infiltrating lymphocytes were associated with improved survival in ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Trastuzumab has become part of the standard of care for the treatment of patients with HER2-positive breast cancer in the metastatic as well as the adjuvant setting. Cardiotoxicity, however ...

Celltrion announced that its Brazilian subsidiary won the Federal Government of Brazil’s bid to supply HERZUMA (trastuzumab-pkrb) for the fifth consecutive year, with around 660,000 vials to be ...